Aramchol (C20-FABAC), also known as arachidyl amido cholanoic acid, is a conjugate of arachidic acid and cholic acid. It reduces ex vivo cholesterol crystallization in native human bile and dissolves pre-formed cholesterol crystals in a dose-dependent manner.

连续三个月给予脂肪酸-胆汁酸结合物Aramchol能显著降低非酒精性脂肪肝(NAFLD)患者的肝脂肪含量。肝脂肪含量的减少呈剂量依赖性，并伴有新陈代谢改善的趋势，表明Aramchol可能用于治疗脂肪肝疾病[1]。

Performed a randomized, double-blind, placebo-controlled trial of 60 patients with biopsy-confirmed NAFLD (6 with nonalcoholic steatohepatitis) at 10 centers in Israel. Patients were given Aramchol (100 or 300 mg) or placebo once daily for 3 months (n = 20/group). The main end point was the difference between groups in the change in liver fat content according to magnetic resonance spectroscopy. The secondary end points focused on the differences between groups in alterations of liver enzyme levels, levels of adiponectin, homeostasis model assessment scores, and endothelial function[1].